TITLE

Formulation,development and Evaluation of film coated tablet containing Cefixime and Potassium clavulanate

AUTHOR(S)
Patel, Sandip Kumar Mangal Bhai; Chaniara, Bhavin R.; Chudasama, J. J.; Shekhawat, Amit S.
PUB. DATE
June 2011
SOURCE
Journal of Pharmacy Research;Jun2011, Vol. 4 Issue 6, p1861
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The considerations for preparation of bilayer tablet of good quality are to prevent cross contamination between two layers,to produce a clear visual separation between two layers,accurate and individual weight control of two layers. B-lactam antibiotic (Cefixime) given with B lactamase inhibitor(Potassium Clavulanate) in treatment of UTI's, otitis media and COPD. But Cefixime occurs as trihydrate form as potassium clavulanate is to much hygroscopic there is possibility to absorb water of crystallization from Cefixime removed during processing step. Therefore here in my study physical separation of the two active ingredient was done by formulating bilayer tablet. Avoidance of absorbing moisture from potassium Clavulanate done by film coating of formulated bilayer core tablet with moist shield instacoat material. Formerly two separate layer were compressed by addition of S.S.G(1%,2%,4%),C.C.S(0.5%,1%,2%) and Kyron T314 (0.5%,1%,2%) as super disintegrants, Avicel PH 102 as diluent, talc (2%) and magnesium stearate(1%) as lubricant,temperature not exceeding 250c and humidity not exceeding 35%R.H.Coating process parameters like atomizing air pressure and inlet air temperature were optimized using 3² full factorial design in Design Expert sowtware 8.0.5.2 Formulated film coated bilayer tablets were evaluated for weight variation,thickness, friability, hardness, disintegration, invitro dissolution and stability study of three months,also compared with marketed product. Results of calculation of similarity factor (f2) shown that ,formulation containing 4%S.S.G,2%C.C.S,2% Kyron T 314 much more similarity to reference product. Formulation batch code CV9 (2%Kyron T 314) shown f2 value 99.78, thus it can also used as super disintegrant as well as dissolution enhancer of Cefixime(BCS Class 4).Bilayer tablet shows much more stability then marketed single layer tablet.
ACCESSION #
74457570

Tags: TABLETS (Medicine) -- Research;  BETA lactam antibiotics;  POTASSIUM;  DRUGS -- Coatings;  DRUG development

 

Related Articles

  • �-Lactams as Inhibitors of Serine Enzymes. Konaklieva, M.I. // Current Medicinal Chemistry - Anti-Infective Agents;Jul2002, Vol. 1 Issue 3, p215 

    For nearly six decades, penicillins have been used widely to treat bacterial infections. The development of multidrug resistance, however, has reduced the effectiveness of �-lactams as antimicrobial drugs. A main contributor to b-lactam resistance is the production of �-lactamases, and...

  • Putting Fungi to Work: Harvesting a Cornucopia of Drugs, Toxins, and Antibiotics. Kück, Ulrich; Bloemendal, Sandra; Teichert, Ines // PLoS Pathogens;Mar2014, Vol. 10 Issue 3, p1 

    The article examines the role of fungi as producers of life-saving drugs. Topics covered include the effects of some fungi on human health such as Aspergillus terreus, Claviceps purpurea and Ashbya gossypii, the role of horizontal gene transfer in the diversity of fungal metabolism, and the...

  • When to use the newer beta-lactam antibiotics. Rosenfeld, Elaine; Shaughnessy, Allen F. // Patient Care;9/15/1995, Vol. 29 Issue 14, p119 

    Studies the use of the new beta-lactam antibiotics and some third generation cephalosporin drugs. Brief on the fungus Cephalosporium acremonium; Description of oral agents Cefixime, Cefpodoxime proxetil, Cefprozil and Loracarbef, and parental agents Ceftazidine, Aztreonam, Imipenem/cilastatin...

  • Beta-Lactam Antibiotic Therapy in Febrile Granulocytopenic Patients. Winston, Drew; Ho, Winston; Bruckner, David; Champlain, Richard // Annals of Internal Medicine;12/1/91, Vol. 115 Issue 11, p849 

    Presents a study which compared the efficacy, toxicity and cost-effectiveness of double beta-lactam therapy with monotheraphy in febrile granulocytopenic patients. Study design; Materials and methods used; Results.

  • Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad-and extended-spectrum beta-lactamases.  // Croatian Medical Journal;2005, Vol. 46 Issue 4, p718 

    Presents an abstract of the study "Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad-and extended-spectrum beta-lactamases," by B. Bedenic et al.

  • Appropriate Prescribing of Oral Beta-Lactam Antibiotics. Holten, Keith B. // American Family Physician;8/1/2000, Vol. 62 Issue 3, p611 

    Beta-lactam antibiotics include penicillins, cephalosporins and related compounds. As a group, these drugs are active against many gram-positive, gram-negative and anaerobic organisms. Information based on "expert opinion" and antimicrobial susceptibility testing supports certain antibiotic...

  • N-Thiolated �-Lactams. Long, T.E.; Turos, E. // Current Medicinal Chemistry - Anti-Infective Agents;Jul2002, Vol. 1 Issue 3, p251 

    N-Thiolated �-lactams are �-lactam compounds that have a sulfur substituent on the nitrogen center. They represent a broad and growing family of bioactive molecules. In this review we provide a summary of the known biological properties of the different classes of N-thiolated...

  • �-Lactamases and their Inhibitors: An Update. Micetich, R.G.; Salama, S.M.; Maiti, S.N.; Reddy, A.V.N.; Singh, R. // Current Medicinal Chemistry - Anti-Infective Agents;Jul2002, Vol. 1 Issue 3, p193 

    The �-lactam antibiotics perhaps form the best studied and most used (in volume and sales) antibiotics in the world today. The extensive and in many cases, uncontrolled use of the �-lactam antibiotics, particularly in developing countries and for veterinary uses, has resulted in the...

  • History of Cerebrovascular Events: A Relative Contraindication to Ertapenem Treatment. Saidel-Odes, Lisa; Borer, Abraham; Riesenberg, Klaris; Smolyakov, Rozalia; Schlaeffer, Francisc // Clinical Infectious Diseases;7/15/2006, Vol. 43 Issue 2, p262 

    A letter to the editor is presented which reports on two cases about an adverse effect associated with the prenatal β-lactam antimicrobial agent, ertapenem.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics